H.C. Wainwright lowered the firm’s price target on Plus Therapeutics (PSTV) to $5.50 from $8 and keeps a Buy rating on the shares. The firm cites the increased number of outstanding shares and warrants associated with the company’s latest placement for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Reports 2024 Financial Results and Progress
- Plus Therapeutics announces FDA conditionally accepted name REYOBIQ
- Plus Therapeutics initiated with a Buy at D. Boral Capital
- Biotech Alert: Searches spiking for these stocks today
- Plus regains compliance with Nasdaq minimum stockholders’ equity requirement